Company news

Clover Biopharmaceuticals Ltd. news in 2026

Clover Biopharmaceuticals Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Monthly Return of Equity Issuer on Movements in Securities for the Month ended October 31, 2026

November 4, 2026

Monthly Return of Equity Issuer on Movements in Securities for the Month ended September 30, 2026

October 7, 2026

2026 Interim Report

September 30, 2026

Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults

September 6, 2026

Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults

March 24, 2026

Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates

January 11, 2026

Decks in 2026